Failure, not just success, should guide future doctors

AdobeMatchDay,whichrolledaroundthisyearonMarch15,isarguablyoneofthemostimportantdaysinadoctor’slife. OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand




hotspot

author：focus    Page View：9215
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： How CRISPR works, explained in two minutes
Next article： Psychedelics group wrestles with new pharma identity